{
    "id": 28868,
    "fullName": "SALL2 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SALL2-BRAF results from the fusion of SALL2 and BRAF (PMID: 29883838), and has not been biochemically characterized, however, due to the effects of other BRAF fusions that result in loss of the BRAF CR1 domain and retention of the protein kinase domain (PMID: 23890088, PMID: 12781369), is predicted to result in a gain of function. SALL2-BRAF has been identified in non-small cell lung cancer (PMID: 29883838).",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                },
                {
                    "id": 3413,
                    "pubMedId": 23890088,
                    "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                },
                {
                    "id": 14743,
                    "pubMedId": 12781369,
                    "title": "Raf proteins and cancer: B-Raf is identified as a mutational target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12781369"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6297,
        "geneSymbol": "SALL2",
        "terms": [
            "SALL2",
            "COLB",
            "HSAL2",
            "p150(Sal2)",
            "Sal-2",
            "ZNF795"
        ]
    },
    "variant": "SALL2 - BRAF",
    "createDate": "10/25/2018",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15126,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib) treatment with a partial response of 30 months, EGFR L858R and SALL2-BRAF were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30771,
                "profileName": "SALL2 - BRAF EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30757,
            "profileName": "SALL2 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30771,
            "profileName": "SALL2 - BRAF EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}